Revocation of CTO and Reinstatement to Trade

BROSSARD, Québec, Feb. 01, 2018 (GLOBE NEWSWIRE) -- ZoomMed Inc. (TSX Venture Exchange:ZMD) (“ZoomMed”) is pleased to announce that the TSX Venture Exchange will be issuing a bulletin to reinstate trading in ZoomMed’s securities for the market opening on February 5, 2018.

Pursuant to Policy Statement 11-207 Respecting Failure-To-File Cease Trade Orders and Revocations in Multiple Jurisdictions, ZoomMed undertakes to hold an annual meeting within 3 months after the date of such revocation.

The CTO issued by the Autorité des Marchés Financiers and the Ontario Securities Commission on October 5, 2017, following the inability of ZoomMed to file its annual audited financial statements for the financial year ended on May 31, 2017, has been revoked this day by both the AMF and the OSC following the filling by ZoomMed of all of its continuous disclosure documents provided by the legislation.

About ZoomMed

ZoomMed builds and operates “ZoomMed’s communication network,” a clinical information exchange platform between physicians and the various other stakeholders of the healthcare sector, such as pharmacists, specialists, pharmaceutical corporations and private insurers.

The cornerstone of this network is ZoomMed's “ZRx Prescriber,” a technologically innovative Web application that greatly simplifies the writing of a prescription for the physician. Since it is a stand-alone product, it can easily be integrated to any Electronic Medical Record application (EMR).

For further information on ZoomMed, contact Mr. Yves Marmet, President and Chief Executive Officer (450) 678-5457, Ext 228, info@zoommed.com or visit our Web Site; www.zoommed.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.